NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, announced today that the company will present at the 21st Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/ 27th Annual International Congress of Chemotherapy (ICC) on May 7th and 8th, 2011, in Milan, Italy. ECCMID/ICC attracts more than ten thousand experts each year, covering key topics of infectious disease including diagnosis, prevention, pathogenesis, treatment, and antibiotic resistance. Rib-X will give a podium talk and present several posters describing the rational design of three unique antibiotic scaffolds with a novel mechanism of action from the Company’s RX-04 development program. Two poster presentations will also provide data on the activity of next-generation antibiotic candidates, delafloxacin and radezolid, against drug-resistant strains of bacteria.
